*6,7 RESTORE-G: RESTORE-G was a real-world analysis in insulin-nave adults with type 2 diabetes mellitus (T2DM) previously treated with GLP-1 receptor agonists (GLP-1 RA) oral antidiabetic drugs (OADs), examining therapy intensification through three approaches involving basal insulin analogues 8 : Starting basal insulin and discontinuing GLP-1 RA Adding basal insulin to ongoing GLP-1 RA Initiating a FRC product and discontinuing current GLP-1 RA 1
Shashank Upadhye, a founding partner of Upadhye Tang LLP an IP & FDA boutique law firm in Chicago and author of Generic Pharmaceutical Patent & FDA Law, a textbook now in its 14th edition, served as chief in-house counsel at three leading pharmaceutical companies: Apotex, Inc., Sandoz-Novartis, and Eon Labs, Inc
Rather, its an eating approach designed to work alongside GLP-1 medications such as Ozempic, Wegovy, and Mounjaro
The cases described by Patil and Mitra (2026) in Addison's disease, by Foster and Murray (2026) in Laugier-Hunziker Syndrome, and by Jindal et al
(Note: some answers in this piece have been trimmed for length and clarity.) Overview Lets start off with the basics
